Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target-Reference-Cited by-同舟云学术

Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target

Published:2018-03-14 Issue:5 Volume:135 Page:757-777
ISSN:0001-6322
Container-title:Acta Neuropathologica
language:en
Short-container-title:Acta Neuropathol

Author:

Apps John R.,Carreno Gabriela,Gonzalez-Meljem Jose Mario,Haston Scott,Guiho Romain,Cooper Julie E.,Manshaei Saba,Jani Nital,Hölsken Annett,Pettorini Benedetta,Beynon Robert J.,Simpson Deborah M.,Fraser Helen C.,Hong Ying,Hallang Shirleen,Stone Thomas J.,Virasami Alex,Donson Andrew M.,Jones David,Aquilina Kristian,Spoudeas Helen,Joshi Abhijit R.,Grundy Richard,Storer Lisa C. D.,Korbonits Márta,Hilton David A.,Tossell Kyoko,Thavaraj Selvam,Ungless Mark A.,Gil Jesus,Buslei Rolf,Hankinson Todd,Hargrave Darren,Goding Colin,Andoniadou Cynthia L.,Brogan Paul,Jacques Thomas S.,Williams Hywel J.,Martinez-Barbera Juan Pedro^ORCID

Funder

Medical Research Council

Cancer Research UK

Children's Cancer and Leukaemia Group

CHILDREN with CANCER UK

Brain Tumour Charity

Great Ormond Street Hospital Charity

National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London

Wellcome Trust

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Neurology (clinical),Pathology and Forensic Medicine

Link

http://link.springer.com/article/10.1007/s00401-018-1830-2/fulltext.html

Reference59 articles.

1. Andoniadou CL, Gaston-Massuet C, Reddy R, Schneider RP, Blasco MA, Le Tissier P, Jacques TS, Pevny LH, Dattani MT, Martinez-Barbera JP (2012) Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol 124:259–271. https://doi.org/10.1007/s00401-012-0957-9

2. Andoniadou CL, Matsushima D, Mousavy Gharavy SN, Signore M, Mackintosh AI, Schaeffer M, Gaston-Massuet C, Mollard P, Jacques TS, Le Tissier P et al (2013) Sox2(+) stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential. Cell Stem Cell 13:433–445. https://doi.org/10.1016/j.stem.2013.07.004

3. Apps JR, Hutchinson JC, Arthurs OJ, Virasami A, Joshi A, Zeller-Plumhoff B, Moulding D, Jacques TS, Sebire NJ, Martinez-Barbera JP (2016) Imaging invasion: micro-CT imaging of adamantinomatous craniopharyngioma highlights cell type specific spatial relationships of tissue invasion. Acta Neuropathol Commun 4:57. https://doi.org/10.1186/s40478-016-0321-8

4. Apps JR, Martinez-Barbera JP (2017) Genetically engineered mouse models of craniopharyngioma: an opportunity for therapy development and understanding of tumor biology. Brain Pathol 27:364–369. https://doi.org/10.1111/bpa.12501

5. Apte RN, Voronov E (2008) Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev 222:222–241. https://doi.org/10.1111/j.1600-065X.2008.00615.x

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-cell and spatial sequencing identifies senescent and germinal tumor cells in adamantinomatous craniopharyngiomas;Cell & Bioscience;2024-09-02

2. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression;Acta Neuropathologica Communications;2024-08-10

3. The oxytocin system in patients with craniopharyngioma: A systematic review;2024-08-01

4. Molecular Developments in Parasellar Tumors and Potential Therapeutic Implications;Endocrine Reviews;2024-07-26

5. Approach to the Patient: New Era Emerges for Craniopharyngioma Management;The Journal of Clinical Endocrinology & Metabolism;2024-07-23